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LETTERS TO THE EDITOR
Measurement of Antistreptokinase Antibodies
The average level of antistreptokinase antibodies in a given pop-
ulation varies and depends on the local incidence of streptococcal
infections. In a study of 120 patients and hospital employees taken
at random, we found 5 (4%) with high antistreptokinase antibodies
necessitatingbetween 180 and 400 IU of streptokinase/ml of plasma
to achieve plasma clot lysis within 10 minutes (I). If such patients
were to undergo thrombolytic therapy with streptokinase, they
would need 600,000 to 1.5 million IU of streptokinase just to
overcome the inhibitory effect of the antistreptokinase antibodies.
Lew et al. (2) recently reported a case of inferoposterior myo-
cardial infarction in which a high titer of antistreptokinase anti-
bodies resulted in the failure of a coronary thrombus to lyse. In
1981, we observed a similar case (3). The patient was a 62 year
old woman presenting with a 24 hour history of increasing chest
pain. At the time of admission, there were signs of an acute anterior
myocardial infarction, and coronary angiography showed complete
occlusion of the left anterior descending coronary artery. Strep-
tokinase (500,000 IU) was infused directly into the left coronary
artery over a 3 hour period. The procedure was then abandoned
because no signs of reopening had occurred. Five hours later, the
results of the antibody determination performed by the technique
of Johnson et al. (4) became known. The patient's antistreptokinase
titer was found to be 250 IU/ml.
Antibodies against thrombolytic agents should be searched for
routinely in patients undergoing thrombolytic therapy in acute
myocardial infarction. Results should be available as soon as pos-
sible to allow adjustment of the amount of streptokinase infused.
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Reply
Sigwart et al. recommended routine measurement of the anti-
streptokinase antibody titer in patients with acute myocardial in-
farction undergoing streptokinase thrombolytic therapy. We agree
that this would facilitate individualization of dosage and rapid
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neutralization of antistreptokinase antibody but we consider that
the potential benefits of adopting such a recommendation are cur-
rently limited because the available accurate assays for antistrep-
tokinase titer cannot usually provide a result rapidly enough to
guide streptokinase dosage during the critical 4 to 6 hour time
interval after the onset of infarction. A second limitation of the
recommendation of Sigwart et al. is that in most patients, the an-
tistreptokinase titer is low relative to the dose of streptokinase and
only occasional patients have a moderate to high antistreptokinase
titer which interferes with fibrinolysis.
In order to identify patients in whom delayed or failed reper-
fusion is likely to be due to a high antistreptokinase titer, we
routinely measure serum fibrinogen immediately after administra-
tion of streptokinase. In our experience, serum fibrinogen falls to
less than 50 mg/l 00 ml in most patients by the end of a 30 minute
intravenous infusion of 750,000 IU of streptokinase and in 12 such
patients that we have treated, no antistreptokinase antibodies were
detected by counterelectrophoresis. In three patients in whom re-
perfusion had not occurred within 60 minutes of streptokinase
administration and in whom the poststreptokinase serum fibrinogen
levels were 285, 175 and 92 mgllOO ml, respectively, the whole
body antistreptokinase titer was between 0.5 and 1.5 million IU.
Reperfusion followed a second infusion of streptokinase in the
latter two of these three patients.
Thus, our experience suggests that a high antistreptokinase titer
may either completely prevent or significantly inhibit thrombo-
lysis. Since the degree of poststreptokinase serum fibrinogen de-
pletion can provide only a delayed and qualitative assessment of
the antistreptokinase titer, a rapid antistreptokinase assay that is
accurate to within 100,000 to 200,000 IU would, therefore, be a
superior measurement which would facilitate an early and defin-
itive adjustment of the dose of streptokinase. Even though anti-
streptokinase antibodies seem to be clinically important in only a
few patients, we agree with Sigwart et al. that the tailoring of the
streptokinase dosage would be of clinical benefit and, therefore, we
encourage efforts to develop and test the utility of a rapid and
accurate antistreptokinase assay.
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Spontaneous Echocardiographic Contrast and
Hepatic Congestion
Hjemdahl-Monsen and colleagues (I) have reported spontaneous
echocardiographic contrast in the inferior vena cava in a patient
with constrictive pericarditis. They suggested that low flow state
enabled the red blood cell aggregates to form and yield spontaneous
contrast. We have observed the occurrence of spontaneous contrast
